Subscribe
servickuz
servickuz / shutterstock.com
9 November 2020EuropeMarkus Grammel

The plausibility battleground at the EPO

The European Patent Office (EPO), as the central organ of the European patent system, rewards inventors or their legal successors for their technical contribution to art with patent monopolies, fostering and stimulating innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
A stricter interpretation: the EPO and antibodies
27 October 2020   Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
Americas
Biosimilars market value could triple by 2020, says report
3 July 2015   The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.
Big Pharma
Is there a step between ‘inventive’ and ‘nonobviousness’?
12 September 2023   Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Biotechnology
A stricter interpretation: the EPO and antibodies
27 October 2020   Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
Americas
Biosimilars market value could triple by 2020, says report
3 July 2015   The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.
Big Pharma
Is there a step between ‘inventive’ and ‘nonobviousness’?
12 September 2023   Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.

More on this story

Biotechnology
A stricter interpretation: the EPO and antibodies
27 October 2020   Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
Americas
Biosimilars market value could triple by 2020, says report
3 July 2015   The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.
Big Pharma
Is there a step between ‘inventive’ and ‘nonobviousness’?
12 September 2023   Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.

More features

Sanofi subsidiary fends off $450m trade secrets case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Cooley adds ex-Gowling partner
Big Pharma counsel embrace AI but data and legal risks loom
HR, lobbying and business strategy…all in a day’s work for today’s counsel
LSPN Fall: Gilead GC shares top drafting tips
LSPN Fall: Why Big Pharma is facing 'a balancing act'